Lloyd E. Damon, MD

Lloyd E. Damon, MD

Clinical Professor, Department of Medicine, UCSF; Director, Hematologic Malignancies and Bone Marrow Transplant, UCSF
Robert O. and Angela W. Johnson Endowed Chair of Hematopoetic Malignancies, UCSF

Phone: (415) 353-2421 (appts)
Box 0324, UCSF
San Francisco, CA 94143-0324

View on UCSF Profiles

Cancer Center Membership

Program Member ยป Hematopoietic Malignancies

Research Summary

I have performed clinical trials in hematologic malignancies and hematopoietic cell transplantation since 1988. My focus has been predominantly in the acute leukemias and lymphomas, with emphasis on novel chemotherapy drug schedules and dosing aimed at enhancing treatment efficacy and/or reducing treatment toxicity. I discovered the relationship of high-dose cytarabine neurotoxicity and renal insufficiency that led to a dose-modification scheme that reduced neurotoxicity risk (this has become the standard of care in physicians using high doses of cytarabine). I have explored methods of adding immunotherapy to autologous hematopoietic cell transplant, most notably the GVAX platform in AML in conjunction with the Johns Hopkins group. I was the national PI on CALGB protocol 59909 adding rituximab and autologous hematopoietic cell transplant to aggressive immunochemotherapy for mantle cell lymphoma. I am the UCSF sub-PI on the Ohio State University Blood and Marrow Transplant Research Consortium within the BMT CTN. I am the campus PI on the new University of California Hematologic Malignancies Research Consortium linking UCSF, UCSD, UCD, UCLA, and UCI to facilitate clinical and collaborative scientific research in blood cancers in California.
My research activities have been tempered by additional clinical and administrative responsibilities since achieving faculty status. Based on the waxing and waning of nonmalignant hematology faculty at UCSF, I have often had to shift my clinical work to nonmalignant activities (outpatient clinic and inpatient consults) multiple times over my career. This has even included a brief term as interim director of our Hemophilia Treatment Center and participation as PI on several clinical trials in nonmalignant hematology. I am currently the director of adult hematology and blood and marrow transplantation at UCSF and the deputy chief of the division of hematology-oncology. I served on the National Comprehensive Cancer Network guideline panels for adult acute myeloid leukemia and acute lymphoblastic leukemia.


Olivet College, Olivet, Michigan, B.A., 1978, Chemistry/Biology
University of Michigan Medical School, Ann Arbor, M.D., 1982, Medicine
University of California San Francisco, Residency, 1985, Internal Medicine
University of California San Francisco, Fellowship, 1988, Hematology/Oncology

Professional Experience

  • 1976-1978
    Instructor, Organic Chemistry Laboratory, Olivet College
  • 1988-1989
    Clinical Instructor of Medicine, Univ. California, San Francisco
  • 1989-1995
    Assistant Clinical Professor of Medicine, Univ. California, San Francisco
  • 1996-2000
    Associate Clinical Professor of Medicine, Univ. California, San Francisco
  • 2000-present
    Clinical Professor of Medicine, Univ. California, San Francisco
  • 1989-Present
    Director, Apheresis and Stem cell Collection Unit, University of California, San Francisco

Honors & Awards

  • 1985
    American Cancer Society Clinical Fellowship Award
  • 2001, 2003
    Faculty teaching award, Division of Hematology-Oncology
  • 2003
    Exceptional Physician Award, UCSF Medical Center
  • 2007
    "Master Clinician" Award, UCSF Department of Medicine

Selected Publications

  1. Alvarnas JC, Brown PA, Aoun P, Ballen KK, Barta SK, Borate U, Boyer MW, Burke PW, Cassaday R, Castro JE, Coccia PF, Coutre SE, Damon LE, DeAngelo DJ, Douer D, Frankfurt O, Greer JP, Johnson RA, Kantarjian HM, Klisovic RB, Kupfer G, Litzow M, Liu A, Rao AV, Shah B, Uy GL, Wang ES, Zelenetz AD, Gregory K, Smith C. Acute Lymphoblastic Leukemia, Version 2.2015. J Natl Compr Canc Netw. 2015 Oct; 13(10):1240-79.
    View on PubMed
  2. Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N, Strickland SA, Schiller GJ, Jabbour E, Erba HP, Pigneux A, Horst HA, Recher C, Klimek VM, Cortes J, Roboz GJ, Odenike O, Thomas X, Havelange V, Maertens J, Derigs HG, Heuser M, Damon L, Powell BL, Gaidano G, Carella AM, Wei A, Hogge D, Craig AR, Fox JA, Ward R, Smith JA, Acton G, Mehta C, Stuart RK, Kantarjian HM. Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. Lancet Oncol. 2015 Sep; 16(9):1025-36.
    View on PubMed
  3. Marra J, Greene J, Hwang J, Du J, Damon L, Martin T, Venstrom JM. KIR and HLA Genotypes Predictive of Low-Affinity Interactions Are Associated with Lower Relapse in Autologous Hematopoietic Cell Transplantation for Acute Myeloid Leukemia. J Immunol. 2015 May 1; 194(9):4222-30.
    View on PubMed
  4. Stone RM, Mazzola E, Neuberg D, Allen SL, Pigneux A, Stuart RK, Wetzler M, Rizzieri D, Erba HP, Damon L, Jang JH, Tallman MS, Warzocha K, Masszi T, Sekeres MA, Egyed M, Horst HA, Selleslag D, Solomon SR, Venugopal P, Lundberg AS, Powell B. Phase III Open-Label Randomized Study of Cytarabine in Combination With Amonafide L-Malate or Daunorubicin As Induction Therapy for Patients With Secondary Acute Myeloid Leukemia. J Clin Oncol. 2015 Apr 10; 33(11):1252-7.
    View on PubMed
  5. Mannis GN, Andreadis C, Logan AC, Damon LE, Benet LZ, Ai WZ, Gaensler KM, Kaplan LD, Koplowicz YB, Linker CA, Olin RL, Sayre PH, Smith CC, Sudhindra A, Venstrom JM, Wolf JL, Martin TG. A phase I study of targeted, dose-escalated intravenous busulfan in combination with Etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015 Jun; 15(6):377-83.
    View on PubMed
  6. Lindsley RC, Mar BG, Mazzola E, Grauman PV, Shareef S, Allen SL, Pigneux A, Wetzler M, Stuart RK, Erba HP, Damon LE, Powell BL, Lindeman N, Steensma DP, Wadleigh M, DeAngelo DJ, Neuberg D, Stone RM, Ebert BL. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 2015 Feb 26; 125(9):1367-76.
    View on PubMed
  7. Mannis GN, Logan AC, Leavitt AD, Yanada M, Hwang J, Olin RL, Damon LE, Andreadis C, Ai WZ, Gaensler KM, Greene CC, Gupta NK, Kaplan LD, Mahindra A, Miyazaki Y, Naoe T, Ohtake S, Sayre PH, Smith CC, Venstrom JM, Wolf JL, Caballero L, Emi N, Martin TG. Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis. Bone Marrow Transplant. 2015 Jan; 50(1):40-4.
    View on PubMed
  8. Keller JW, Andreadis C, Damon LE, Kaplan LD, Martin TG, Wolf JL, Ai WZ, Venstrom JM, Smith CC, Gaensler KM, Hwang J, Olin RL. Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients. J Geriatr Oncol. 2014 Jul; 5(3):238-44.
    View on PubMed
  9. Lancet JE, Cortes JE, Hogge DE, Tallman MS, Kovacsovics TJ, Damon LE, Komrokji R, Solomon SR, Kolitz JE, Cooper M, Yeager AM, Louie AC, Feldman EJ. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML. Blood. 2014 May 22; 123(21):3239-46.
    View on PubMed
  10. O'Donnell MR, Tallman MS, Abboud CN, Altman JK, Appelbaum FR, Arber DA, Attar E, Borate U, Coutre SE, Damon LE, Lancet J, Maness LJ, Marcucci G, Martin MG, Millenson MM, Moore JO, Ravandi F, Shami PJ, Smith BD, Stone RM, Strickland SA, Wang ES, Gregory KM, Naganuma M. Acute myeloid leukemia, version 2.2013. J Natl Compr Canc Netw. 2013 Sep 1; 11(9):1047-55.
    View on PubMed
  11. Baikaidi M, Chung SS, Tallman MS, Damon LE, Walker AR, Marcucci G, Sholi AM, Morris GJ. A 75-year-old woman with thoracic spinal cord compression and chloroma (granulocytic sarcoma). Semin Oncol. 2012 Dec; 39(6):e37-46.
    View on PubMed
  12. Rubenstein JL, Li J, Chen L, Advani R, Drappatz J, Gerstner E, Batchelor T, Krouwer H, Hwang J, Auerback G, Kadoch C, Lowell C, Munster P, Cha S, Shuman MA, Damon LE. Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma. Blood. 2013 Jan 31; 121(5):745-51.
    View on PubMed
  13. O'Brien S, Schiller G, Lister J, Damon L, Goldberg S, Aulitzky W, Ben-Yehuda D, Stock W, Coutre S, Douer D, Heffner LT, Larson M, Seiter K, Smith S, Assouline S, Kuriakose P, Maness L, Nagler A, Rowe J, Schaich M, Shpilberg O, Yee K, Schmieder G, Silverman JA, Thomas D, Deitcher SR, Kantarjian H. High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia. J Clin Oncol. 2013 Feb 20; 31(6):676-83.
    View on PubMed
  14. Greenberg PL, Garcia-Manero G, Moore M, Damon L, Roboz G, Hu K, Yang AS, Franklin J. A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine. Leuk Lymphoma. 2013 Feb; 54(2):321-8.
    View on PubMed
  15. O'Donnell MR, Abboud CN, Altman J, Appelbaum FR, Arber DA, Attar E, Borate U, Coutre SE, Damon LE, Goorha S, Lancet J, Maness LJ, Marcucci G, Millenson MM, Moore JO, Ravandi F, Shami PJ, Smith BD, Stone RM, Strickland SA, Tallman MS, Wang ES, Naganuma M, Gregory KM. Acute myeloid leukemia. J Natl Compr Canc Netw. 2012 Aug; 10(8):984-1021.
    View on PubMed
  16. Alvarnas JC, Brown PA, Aoun P, Ballen KK, Bellam N, Blum W, Boyer MW, Carraway HE, Coccia PF, Coutre SE, Cultrera J, Damon LE, DeAngelo DJ, Douer D, Frangoul H, Frankfurt O, Goorha S, Millenson MM, O'Brien S, Petersdorf SH, Rao AV, Terezakis S, Uy G, Wetzler M, Zelenetz AD, Naganuma M, Gregory KM. Acute lymphoblastic leukemia. J Natl Compr Canc Netw. 2012 Jul 1; 10(7):858-914.
    View on PubMed
  17. Porzig A, Matthay KK, Dubois S, Pampaloni M, Damon L, Hawkins R, Goldsby R, Hollinger F, Fitzgerald P. Proteinuria in metastatic pheochromocytoma is associated with an increased risk of Acute Respiratory Distress Syndrome, spontaneously or after therapy with 131I-meta-iodobenzylguanidine (131I-MIBG). Horm Metab Res. 2012 Jun; 44(7):539-42.
    View on PubMed
  18. Van Loon K, Gill RM, McMahon P, Chigurupati R, Siddiqi I, Fox L, Damon L, McCalmont TH, Jordan R, Wolf J. 20q- clonality in a case of oral sweet syndrome and myelodysplasia. Am J Clin Pathol. 2012 Feb; 137(2):310-5.
    View on PubMed
  19. Wieduwilt MJ, Valles F, Issa S, Behler CM, Hwang J, McDermott M, Treseler P, O'Brien J, Shuman MA, Cha S, Damon LE, Rubenstein JL. Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI. Clin Cancer Res. 2012 Feb 15; 18(4):1146-55.
    View on PubMed
  20. Liu H, Johnson JL, Koval G, Malnassy G, Sher D, Damon LE, Hsi ED, Bucci DM, Linker CA, Cheson BD, Stock W. Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909. Haematologica. 2012 Apr; 97(4):579-85.
    View on PubMed

Go to UCSF Profiles, powered by CTSI